AbbraTech Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $8.51M

  • Investors
  • 4

AbbraTech General Information

Description

Developer of an antibody discovery and development services platform designed to produce high-affinity recombinant proteins. The company's services include antigen and project design, recombinant antibody development, antibody optimization, and antibody production, enabling clients to address the current problems in the antibody development paradigm.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 25 Business Park Drive
  • Suite C
  • Branford, CT 06405
  • United States
+1 (203)
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 25 Business Park Drive
  • Suite C
  • Branford, CT 06405
  • United States
+1 (203)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbbraTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 06-Feb-2024 $8.51M Completed Generating Revenue
4. Seed Round 29-Jun-2022 Completed Generating Revenue
3. Grant 01-Jun-2022 Completed Generating Revenue
2. Grant 01-Apr-2022 $339K $3.65M Completed Generating Revenue
1. Seed Round 04-Mar-2021 $3.65M $3.65M Completed Generating Revenue
To view AbbraTech’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AbbraTech Patents

AbbraTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4656203-A1 Compositions and methods for optimized igg production Pending 02-Jun-2024
US-20250369983-A1 Compositions and methods for optimized igg production Pending 02-Jun-2024
EP-4608446-A1 Chimeric antibodies and methods of making and using same Pending 26-Oct-2022
US-20260139036-A1 Chimeric antibodies and methods of making and using same Pending 26-Oct-2022
WO-2024092073-A1 Chimeric antibodies and methods of making and using same Inactive 26-Oct-2022 C07K16/1145
To view AbbraTech’s complete patent history, request access »

AbbraTech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbbraTech Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Meltwind Advisory Venture Capital Minority
Elm Street Ventures VC-Backed Company Minority
National Institutes of Health Government
Connecticut Innovations Venture Capital Minority
To view AbbraTech’s complete investors history, request access »

AbbraTech FAQs

  • When was AbbraTech founded?

    AbbraTech was founded in 2020.

  • Where is AbbraTech headquartered?

    AbbraTech is headquartered in Branford, CT.

  • What is the size of AbbraTech?

    AbbraTech has 7 total employees.

  • What industry is AbbraTech in?

    AbbraTech’s primary industry is Biotechnology.

  • Is AbbraTech a private or public company?

    AbbraTech is a Private company.

  • What is AbbraTech’s current revenue?

    The current revenue for AbbraTech is .

  • How much funding has AbbraTech raised over time?

    AbbraTech has raised $13.8M.

  • Who are AbbraTech’s investors?

    Meltwind Advisory, Elm Street Ventures, National Institutes of Health, and Connecticut Innovations have invested in AbbraTech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process